Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • wuhoucdc
    Member
    • Oct 2009
    • 14

    #1

    The so-call third-generation sequencing coming, but is it credible?

    Hi all,

    I just read the following paper named Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays from Science Express. In this paper, a sequencing corporation, Complete Genomics, Inc., located at Mountain View, CA announced they will release the so-called third-generation sequecing technology with high coverage (45- to 87-fold coverage per genome) and very low price ($4,400). I was attracted deeply by this paper but with suspicion on this. So I try to contact with this corporation using its service email. But it's unfortunate that I have got any response even though 3 emails were sent until now. So I attach the abstract of this paper here and hope you can perform a evaluation on this so-called new technology. Thank you.

    Regards,

    Wuhoucdc

    PS: Published Online November 5, 2009
    Science DOI: 10.1126/science.1181498
    Science Express Index

    Reports
    Submitted on September 3, 2009
    Accepted on October 23, 2009



    Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays
    Radoje Drmanac 1*, Andrew B. Sparks 1, Matthew J. Callow 1, Aaron L. Halpern 1, Norman L. Burns 1, Bahram G. Kermani 1, Paolo Carnevali 1, Igor Nazarenko 1, Geoffrey B. Nilsen 1, George Yeung 1, Fredrik Dahl 2, Andres Fernandez 1, Bryan Staker 1, Krishna P. Pant 1, Jonathan Baccash 1, Adam P. Borcherding 1, Anushka Brownley 1, Ryan Cedeno 1, Linsu Chen 1, Dan Chernikoff 1, Alex Cheung 1, Razvan Chirita 1, Benjamin Curson 1, Jessica C. Ebert 1, Coleen R. Hacker 1, Robert Hartlage 1, Brian Hauser 1, Steve Huang 1, Yuan Jiang 1, Vitali Karpinchyk 1, Mark Koenig 1, Calvin Kong 1, Tom Landers 1, Catherine Le 1, Jia Liu 1, Celeste E. McBride 1, Matt Morenzoni 1, Robert E. Morey 3, Karl Mutch 1, Helena Perazich 1, Kimberly Perry 1, Brock A. Peters 1, Joe Peterson 1, Charit L. Pethiyagoda 1, Kaliprasad Pothuraju 1, Claudia Richter 1, Abraham M. Rosenbaum 4, Shaunak Roy 1, Jay Shafto 1, Uladzislau Sharanhovich 1, Karen W. Shannon 5, Conrad G. Sheppy 1, Michel Sun 1, Joseph V. Thakuria 4, Anne Tran 1, Dylan Vu 1, Alexander Wait Zaranek 4, Xiaodi Wu 6, Snezana Drmanac 1, Arnold R. Oliphant 1, William C. Banyai 1, Bruce Martin 1, Dennis G. Ballinger 1*, George M. Church 4, Clifford A. Reid 1
    1 Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, CA 94043, USA.
    2 Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, CA 94043, USA.; Present address: Ion Torrent Systems, San Francisco, CA, USA.
    3 Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, CA 94043, USA.; Present address: San Diego State University, San Diego, CA, USA.
    4 Department of Genetics, Harvard Medical School, Cambridge, MA, USA.
    5 Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, CA 94043, USA.; Present address: Life Technologies, Carlsbad, CA, USA.
    6 School of Medicine, Washington University, St. Louis, St. Louis, MO, USA.


    * To whom correspondence should be addressed.
    Radoje Drmanac , E-mail: [email protected]
    Dennis G. Ballinger , E-mail: [email protected]


    These authors contributed equally to this work.

    Genome sequencing of large numbers of individuals promises to advance the understanding, treatment, and prevention of human diseases, among other applications. We describe a genome sequencing platform that achieves efficient imaging and low reagent consumption with combinatorial probe anchor ligation (cPAL) chemistry to independently assay each base from patterned nanoarrays of self-assembling DNA nanoballs (DNBs). We sequenced three human genomes with this platform, generating an average of 45- to 87-fold coverage per genome and identifying 3.2 to 4.5 million sequence variants per genome. Validation of one genome data set demonstrates a sequence accuracy of about 1 false variant per 100 kilobases. The high-accuracy, affordable cost of $4,400 for sequencing consumables and scalability of this platform enable complete human genome sequencing for the detection of rare variants in large-scale genetic studies.
    Last edited by wuhoucdc; 11-11-2009, 01:52 PM. Reason: Change the title
  • dbailey
    Junior Member
    • Nov 2009
    • 5

    #2
    Hi Wuhoucdc,

    For some more information about this paper, I encourage you to review our website (http://www.completegenomics.com/data...ngResults.aspx).

    If you have some specific questions, we would be happy to address. You can contact us at [email protected] for general information or at [email protected] for more detailed analysis support.

    Regards,
    Dione

    Comment

    • wuhoucdc
      Member
      • Oct 2009
      • 14

      #3
      Hi Dione,

      After read more carefully on your website about this new technology, I think it will be applied rapidly on various domains. I hope this technology will bring us new chance among human genomics. Thank you.

      Best,

      Wuhoucdc

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
        by SEQadmin2




        NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
        Today, 06:46 AM
      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 10-28-2026, 09:57 AM
      0 responses
      24 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-28-2026, 09:51 AM
      0 responses
      15 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-22-2026, 11:13 AM
      0 responses
      68 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-22-2026, 10:48 AM
      0 responses
      48 views
      0 reactions
      Last Post SEQadmin2  
      Working...